Twice-daily application of ruxolitinib cream demonstrated an ability to reduce itching and blistering in prurigo nodularis, a ...

Lineage Cell Therapeutics (NYSEAMERICAN:LCTX – Free Report) had its price objective reduced by B. Riley from $4.00 to $3.00 in a research note released on Friday,Benzinga reports. They currently have ...

Despite being a mainstay of Parkinson's disease treatment, levodopa, a dopamine-replenishing medication, can cause nasty side ...

Clinical trials are the foundation of modern medicine, shaping the treatments and therapies that improve and save lives.

Sutro Biopharma (NASDAQ:STRO – Get Free Report) was downgraded by research analysts at Wedbush from an “outperform” rating to a “neutral” rating in a research note issued on Friday, MarketBeat.com ...

Q4 2024 Earnings Call Transcript March 13, 2025 Allogene Therapeutics, Inc. beats earnings expectations. Reported EPS is ...

National MS Education and Awareness Month is celebrated each year in the US in March, after having been launched in 2003 by ...

We recently published a list of Top 10 Insider Purchases Last Month. In this article, we are going to take a look at where ...

Goldman Sachs initiated coverage of 89bio (ETNB) with a Neutral rating and $11 price target 89bio is a late-stage clinical company focused on ...

AL002 misses Phase 2 goal in early Alzheimer's. Key Phase 3 data for latozinemab in 2025. Click here to read why ALEC is a ...

Dyne Therapeutics’ DYNE-101 shows positive results in phase 1/2 ACHIEVE study. Read why DYN stock may rise with FDA approval and a $2.78B market opportunity.

Phase 2 TRANQUILITY trial in patients with elevated high-sensitivity C-reactive protein and chronic kidney disease over-enrolled to 143 total ...